20146-63-8

Basic information

• Product Name: 2-BROMO-4-NITROQUINOLINE
• Synonyms: 2-BROMO-4-NITROQUINOLINE
• CAS NO: 20146-63-8
• Molecular Formula: C₉H₅BrN₂O₂
• Molecular Weight: 253.0522
• Mol File: 20146-63-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 362.4 °C at 760 mmHg
• Flash Point: 173 °C
• Appearance: /
• Density: 1.747 g/cm³
• Vapor Pressure: 4.04E-05mmHg at 25°C
• Refractive Index: 1.707
• CAS DataBase Reference: 2-BROMO-4-NITROQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-4-NITROQUINOLINE(20146-63-8)
• EPA Substance Registry System: 2-BROMO-4-NITROQUINOLINE(20146-63-8)

Safety Data

• Hazardous Substances Data: 20146-63-8(Hazardous Substances Data)

Usage

General Description

2-Bromo-4-nitroquinoline is a chemical compound with the molecular formula C9H5BrN2O2. It falls under the category of organobromides and nitrocompounds, and it is part of the broader quinoline family of compounds, a class of heterocyclic aromatic organic compounds. It features a quinoline core structure, with a bromine atom attached at the 2-position and a nitro group attached at the 4-position. Due to its chemical properties, 2-Bromo-4-nitroquinoline is often utilized as a reagent or intermediate in organic synthesis. Information about its specific uses, biochemical behavior, and toxicity may vary and should be consulted for in relevant specialist resources.

InChI:InChI=1/C9H5BrN2O2/c10-9-5-8(12(13)14)6-3-1-2-4-7(6)11-9/h1-5H

Upstream product

• 56-57-5 4-nitroquinoline-N-oxide 
• 67-66-3 chloroform 
• 7789-60-8 phosphorus tribromide 
• 141-78-6 ethyl acetate 

Downstream Products

• 20151-40-0 2,4-dibromoquinoline 
• 36825-35-1 2-bromoquinolin-4-ylamine 
• 1246093-98-0 tert-butyl methyl(4-(4-nitroquinolin-2-yl)phenyl)carbamate 
• 1313359-28-2 tert-butyl methyl(4-(4-fluoroquinolin-2-yl)phenyl)carbamate 

Relevant articles and documents

Amination of 4-nitroquinoline with liquid methylamine/potassium permanganate

-

For detecting imaging agent of neurological disorders

Imaging agents of formulas (I)-(V) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formulas (I)-(V) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formulas (I)-(V) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.

Imaging agents for detecting neurological disorders

Imaging agents of formula (I) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formula (I) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formula (I) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.